Safety and Efficacy of Novel Incretin Co-agonist Cotadutide in Biopsy-proven Noncirrhotic MASH With Fibrosis
Open Access
- 9 May 2024
- journal article
- research article
- Published by Elsevier in Clinical Gastroenterology and Hepatology
- Vol. 22 (9) , 1847-1857.e11
Abstract
No abstract availableKeywords
Funding Information
- Gilead Sciences
- Novartis
- AstraZeneca
This publication has 25 references indexed in Scilit:
- NAFLD/NASHJournal of Hepatology, 2022
- Type 2 diabetes mellitus increases the risk of hepatic fibrosis in individuals with obesity and nonalcoholic fatty liver diseaseObesity, 2021
- Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trialThe Lancet, 2019
- Bariatric surgery improves nonalcoholic fatty liver disease: a contemporary systematic review and meta-analysisSurgery for Obesity and Related Diseases, 2019
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trialThe Lancet, 2018
- MEDI0382, a GLP-1 and glucagon receptor dual agonist, in obese or overweight patients with type 2 diabetes: a randomised, controlled, double-blind, ascending dose and phase 2a studyThe Lancet, 2018
- The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver DiseasesHepatology, 2017
- Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysisHepatology, 2017
- Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomesHepatology, 2015
- The Natural History of Nonalcoholic Steatohepatitis: A Follow–Up Study of Forty–Two Patients for Up to 21 YearsHepatology, 1990